Inclisiran (Italian Wikipedia)

Analysis of information sources in references of the Wikipedia article "Inclisiran" in Italian language version.

refsWebsite

Global rank Italian rank

9doi.org

2^nd place

7^th place

5nih.gov

4^th place

9^th place

3europa.eu

68^th place

57^th place

3nejm.org

2,374^th place

1,283^rd place

3worldcat.org

5^th place

26^th place

3unibo.it

4,963^rd place

325^th place

2oadoi.org

799^th place

22^nd place

1agenziafarmaco.gov.it

low place

1,603^rd place

1who.int

195^th place

342^nd place

1fiercebiotech.com

low place

1globenewswire.com

2,614^th place

4,188^th place

1jacc.org

low place

1today.it

4,283^rd place

160^th place

1msn.com

117^th place

266^th place

1gazzettaufficiale.it

2,836^th place

107^th place

1nice.org.uk

3,258^th place

8,692^nd place

agenziafarmaco.gov.it

farmaci.agenziafarmaco.gov.it

Scheda tecnica AIFA inclisiran, su farmaci.agenziafarmaco.gov.it.

doi.org

dx.doi.org

(EN) Kausik K. Ray, R. Scott Wright e David Kallend, Two Phase 3 Trials of Inclisiran in Patients with Elevated LDL Cholesterol, in New England Journal of Medicine, vol. 382, n. 16, 16 aprile 2020, pp. 1507–1519, DOI:10.1056/NEJMoa1912387. URL consultato il 22 ottobre 2021.
Fitzgerald K, White S, Borodovsky A, Bettencourt BR, Strahs A, Clausen V, Wijngaard P, Horton JD, Taubel J, Brooks A, Fernando C, Kauffman RS, Kallend D, Vaishnaw A, Simon A, A Highly Durable RNAi Therapeutic Inhibitor of PCSK9, in The New England Journal of Medicine, vol. 376, n. 1, gennaio 2017, pp. 41–51, DOI:10.1056/NEJMoa1609243, PMC 5778873, PMID 27959715.
(EN) Frederick J. Raal, David Kallend e Kausik K. Ray, Inclisiran for the Treatment of Heterozygous Familial Hypercholesterolemia, in New England Journal of Medicine, vol. 382, n. 16, 16 aprile 2020, pp. 1520–1530, DOI:10.1056/NEJMoa1913805. URL consultato il 22 ottobre 2021.
Paola Gargiulo, Federica Marzano e Mario Crisci, Real-World Efficacy and Safety of Inclisiran, in Journal of the American College of Cardiology, vol. 0, n. 0, DOI:10.1016/j.jacc.2024.10.106. URL consultato il 16 dicembre 2024.
Diane S. Aschenbrenner, New Adjunct Therapy for Elevated Lipid Levels, in The American journal of nursing, vol. 122, n. 4, Ovid Technologies (Wolters Kluwer Health), 1º aprile 2022, pp. 20–20, DOI:10.1097/01.naj.0000827308.02881.4a, ISSN 0002-936X (WC · ACNP), PMID 35348511.
(EN) Anastasia Khvorova, Oligonucleotide Therapeutics — A New Class of Cholesterol-Lowering Drugs, in New England Journal of Medicine, vol. 376, n. 1, 5 gennaio 2017, pp. 4–7, DOI:10.1056/NEJMp1614154. URL consultato il 22 ottobre 2021.
Gavin M. Traber e Ai-Ming Yu, RNAi Based Therapeutics and Novel RNA Bioengineering Technologies, in The Journal of pharmacology and experimental therapeutics, American Society for Pharmacology & Experimental Therapeutics (ASPET), 9 giugno 2022, pp. JPET–MR–2022–001234, DOI:10.1124/jpet.122.001234, ISSN 0022-3565 (WC · ACNP), PMID 35680378.
Sumit Gangopadhyay e Kiran R Gore, Advances in siRNA therapeutics and synergistic effect on siRNA activity using emerging dual ribose modifications, in RNA biology, vol. 19, n. 1, Informa UK Limited, 30 marzo 2022, pp. 452–467, DOI:10.1080/15476286.2022.2052641, ISSN 1547-6286 (WC · ACNP), PMC 8973385, PMID 35352626.
Anastasia Khvorova, Oligonucleotide Therapeutics - A New Class of Cholesterol-Lowering Drugs, in The New England Journal of Medicine, vol. 376, n. 1, 5 gennaio 2017, pp. 4–7, DOI:10.1056/NEJMp1614154. URL consultato il 22 dicembre 2022.

europa.eu

ema.europa.eu

(IT) Informazioni EMA (PDF), su ema.europa.eu. URL consultato il 25 marzo 2021.
Leqvio: EMA Summary of the product characteristics, su ema.europa.eu.
Conferenza stampa CHMP, su ema.europa.eu.

fiercebiotech.com

Nick Paul Taylor, Medicines Company's PCSK9 drug hits phase 3 efficacy goals, in FierceBiotech, 26 agosto 2019.

gazzettaufficiale.it

Gazzetta Ufficiale, su www.gazzettaufficiale.it. URL consultato il 22 dicembre 2022.

globenewswire.com

ml-eu.globenewswire.com

(EN) Nota stampa Novartis, su ml-eu.globenewswire.com. URL consultato il 25 marzo 2021.

jacc.org

Paola Gargiulo, Federica Marzano e Mario Crisci, Real-World Efficacy and Safety of Inclisiran, in Journal of the American College of Cardiology, vol. 0, n. 0, DOI:10.1016/j.jacc.2024.10.106. URL consultato il 16 dicembre 2024.

msn.com

Alessandro Ferro, Due iniezioni all'anno per dimezzare il colesterolo: come funziona il farmaco, su www.msn.com. URL consultato il 16 dicembre 2024. Ospitato su Il Giornale.

nejm.org

(EN) Kausik K. Ray, R. Scott Wright e David Kallend, Two Phase 3 Trials of Inclisiran in Patients with Elevated LDL Cholesterol, in New England Journal of Medicine, vol. 382, n. 16, 16 aprile 2020, pp. 1507–1519, DOI:10.1056/NEJMoa1912387. URL consultato il 22 ottobre 2021.
(EN) Frederick J. Raal, David Kallend e Kausik K. Ray, Inclisiran for the Treatment of Heterozygous Familial Hypercholesterolemia, in New England Journal of Medicine, vol. 382, n. 16, 16 aprile 2020, pp. 1520–1530, DOI:10.1056/NEJMoa1913805. URL consultato il 22 ottobre 2021.
(EN) Anastasia Khvorova, Oligonucleotide Therapeutics — A New Class of Cholesterol-Lowering Drugs, in New England Journal of Medicine, vol. 376, n. 1, 5 gennaio 2017, pp. 4–7, DOI:10.1056/NEJMp1614154. URL consultato il 22 ottobre 2021.

nice.org.uk

Nice announcement, su nice.org.uk.

nih.gov

ncbi.nlm.nih.gov

Fitzgerald K, White S, Borodovsky A, Bettencourt BR, Strahs A, Clausen V, Wijngaard P, Horton JD, Taubel J, Brooks A, Fernando C, Kauffman RS, Kallend D, Vaishnaw A, Simon A, A Highly Durable RNAi Therapeutic Inhibitor of PCSK9, in The New England Journal of Medicine, vol. 376, n. 1, gennaio 2017, pp. 41–51, DOI:10.1056/NEJMoa1609243, PMC 5778873, PMID 27959715.
Diane S. Aschenbrenner, New Adjunct Therapy for Elevated Lipid Levels, in The American journal of nursing, vol. 122, n. 4, Ovid Technologies (Wolters Kluwer Health), 1º aprile 2022, pp. 20–20, DOI:10.1097/01.naj.0000827308.02881.4a, ISSN 0002-936X (WC · ACNP), PMID 35348511.
Gavin M. Traber e Ai-Ming Yu, RNAi Based Therapeutics and Novel RNA Bioengineering Technologies, in The Journal of pharmacology and experimental therapeutics, American Society for Pharmacology & Experimental Therapeutics (ASPET), 9 giugno 2022, pp. JPET–MR–2022–001234, DOI:10.1124/jpet.122.001234, ISSN 0022-3565 (WC · ACNP), PMID 35680378.
Sumit Gangopadhyay e Kiran R Gore, Advances in siRNA therapeutics and synergistic effect on siRNA activity using emerging dual ribose modifications, in RNA biology, vol. 19, n. 1, Informa UK Limited, 30 marzo 2022, pp. 452–467, DOI:10.1080/15476286.2022.2052641, ISSN 1547-6286 (WC · ACNP), PMC 8973385, PMID 35352626.

pubmed.ncbi.nlm.nih.gov

Anastasia Khvorova, Oligonucleotide Therapeutics - A New Class of Cholesterol-Lowering Drugs, in The New England Journal of Medicine, vol. 376, n. 1, 5 gennaio 2017, pp. 4–7, DOI:10.1056/NEJMp1614154. URL consultato il 22 dicembre 2022.

oadoi.org

Diane S. Aschenbrenner, New Adjunct Therapy for Elevated Lipid Levels, in The American journal of nursing, vol. 122, n. 4, Ovid Technologies (Wolters Kluwer Health), 1º aprile 2022, pp. 20–20, DOI:10.1097/01.naj.0000827308.02881.4a, ISSN 0002-936X (WC · ACNP), PMID 35348511.
Gavin M. Traber e Ai-Ming Yu, RNAi Based Therapeutics and Novel RNA Bioengineering Technologies, in The Journal of pharmacology and experimental therapeutics, American Society for Pharmacology & Experimental Therapeutics (ASPET), 9 giugno 2022, pp. JPET–MR–2022–001234, DOI:10.1124/jpet.122.001234, ISSN 0022-3565 (WC · ACNP), PMID 35680378.

today.it

Farmaco a mRNA dimezza il colesterolo cattivo con due iniezione l'anno, su Today. URL consultato il 16 dicembre 2024.

unibo.it

acnpsearch.unibo.it

Diane S. Aschenbrenner, New Adjunct Therapy for Elevated Lipid Levels, in The American journal of nursing, vol. 122, n. 4, Ovid Technologies (Wolters Kluwer Health), 1º aprile 2022, pp. 20–20, DOI:10.1097/01.naj.0000827308.02881.4a, ISSN 0002-936X (WC · ACNP), PMID 35348511.
Gavin M. Traber e Ai-Ming Yu, RNAi Based Therapeutics and Novel RNA Bioengineering Technologies, in The Journal of pharmacology and experimental therapeutics, American Society for Pharmacology & Experimental Therapeutics (ASPET), 9 giugno 2022, pp. JPET–MR–2022–001234, DOI:10.1124/jpet.122.001234, ISSN 0022-3565 (WC · ACNP), PMID 35680378.
Sumit Gangopadhyay e Kiran R Gore, Advances in siRNA therapeutics and synergistic effect on siRNA activity using emerging dual ribose modifications, in RNA biology, vol. 19, n. 1, Informa UK Limited, 30 marzo 2022, pp. 452–467, DOI:10.1080/15476286.2022.2052641, ISSN 1547-6286 (WC · ACNP), PMC 8973385, PMID 35352626.

who.int

Proposed INN: List 114, in WHO Drug Information, vol. 29, n. 4, WHO, 2015, pp. 531f.

worldcat.org

Diane S. Aschenbrenner, New Adjunct Therapy for Elevated Lipid Levels, in The American journal of nursing, vol. 122, n. 4, Ovid Technologies (Wolters Kluwer Health), 1º aprile 2022, pp. 20–20, DOI:10.1097/01.naj.0000827308.02881.4a, ISSN 0002-936X (WC · ACNP), PMID 35348511.
Gavin M. Traber e Ai-Ming Yu, RNAi Based Therapeutics and Novel RNA Bioengineering Technologies, in The Journal of pharmacology and experimental therapeutics, American Society for Pharmacology & Experimental Therapeutics (ASPET), 9 giugno 2022, pp. JPET–MR–2022–001234, DOI:10.1124/jpet.122.001234, ISSN 0022-3565 (WC · ACNP), PMID 35680378.
Sumit Gangopadhyay e Kiran R Gore, Advances in siRNA therapeutics and synergistic effect on siRNA activity using emerging dual ribose modifications, in RNA biology, vol. 19, n. 1, Informa UK Limited, 30 marzo 2022, pp. 452–467, DOI:10.1080/15476286.2022.2052641, ISSN 1547-6286 (WC · ACNP), PMC 8973385, PMID 35352626.